These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9725540)

  • 1. The relevance of T-type calcium antagonists: a profile of mibefradil.
    Glasser SP
    J Clin Pharmacol; 1998 Aug; 38(8):659-69. PubMed ID: 9725540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
    Waeber B
    Cardiology; 1998; 89 Suppl 1():16-22. PubMed ID: 9570425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN; Markham A
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists.
    Hermsmeyer K; Mishra S; Miyagawa K; Minshall R
    Clin Ther; 1997; 19 Suppl A():18-26. PubMed ID: 9385502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mibefradil: a selective T-type calcium antagonist.
    Massie BM
    Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.
    Triggle DJ
    Am J Cardiol; 1996 Nov; 78(9A):7-12. PubMed ID: 8903279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
    Oparil S
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):88S-94S. PubMed ID: 9607372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats.
    Nakamura Y; Ono H; Frohlich ED
    Hypertension; 1999 Aug; 34(2):273-8. PubMed ID: 10454453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity of calcium antagonists.
    Pitt B
    Clin Ther; 1997; 19 Suppl A():3-17. PubMed ID: 9385501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
    Pordy R; Woittiez A
    Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats.
    Vacher E; Richer C; Fornes P; Clozel JP; Giudicelli
    J Cardiovasc Pharmacol; 1996 May; 27(5):686-94. PubMed ID: 8859939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
    Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
    Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
    Welker HA
    J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker.
    Clozel JP; Ertel EA; Ertel SI
    J Hypertens Suppl; 1997 Dec; 15(5):S17-25. PubMed ID: 9481612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
    Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
    J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.